Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
|
|
- Maurice Rogers
- 6 years ago
- Views:
Transcription
1 Prequalification of Medicines Programme SOP Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1 General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Hetero Laboratories Limited Unit IX Production Block HLL (6 Production Blocks A, B, D, H2, H3, H4 and 2 Pharma sections) HDL (5 Production Blocks A, B, D, H1, H2 and 1 Pharma section) Physical address Contact person and address. Date of inspection Type of inspection Ingredient(s) included in the inspection Summary of the activities performed by the manufacturer Plot No 1 & 2, Hetero Infrastructure LTD, SEZ, N.Narasapuram (Vill), Nakkapally (Mandal), Vishakhapatnam (Dist), Andhra Pradesh. INDIA Dr C. Raghunath Vice President QA & RA (APIs) Hetero Labs Ltd. Telephone Office /24/25, extn 2089 Mobile raghunath.c@heterodrugs.com Routine GMP inspection Hetero Drugs Ltd (HDL) 1. Acyclovir (HDL) APIMF Ritonavir Form I (HDL) APIMF Valganciclovir Hydrochloride (HDL) APIMF 254 Hetero Labs Ltd (HLL) 1. Abacavir Sulfate (HLL) APIMF Efavirenz (HLL) APIMF Emtricitabine (HLL) APIMF Lamivudine (HLL) APIMF Nevirapine Anhydrous (HLL) APIMF Tenofovir Disoproxil Fumarate (HLL) APIMF Zidovudine (HLL) APIMF 124 Production and quality control of active pharmaceutical ingredients (APIs) Page 1 of 7 WHO Public Inspection Report (WHOPIR)
2 Part 2 Summary General information about the company and site The sites inspected were Hetero Labs Limited (HLL) and (HDL), Unit-IX, Plot No 1 & 2, Hetero Infrastructure LTD, SEZ, N.Narasapuram (Vill), Nakkapally (Mandal), Vishakhapatnam (Dist), Andhra Pradesh,, hereafter called HLL Unit IX and HDL Unit IX respectively. Both are owned by Hetero corporate based in Hyderabad. The company corporate office is located at 7-2- A2, Industrial Estates, Sanath Nagar, Hyderabad , Andra Pradesh,. The location is about 84 km away from the Vishakhapatnam Airport. There are 468 employees in HDL and 1125 in HLL. According to the presentation given at the opening meeting, Hetero Labs Limited was established in April 1998, and following details were presented regarding Hetero manufacturing sites Name of the division Location Business unit Hetero Corporate Hetero Foundation Research Unit-IX Hetero Labs Limited Unit-IX Unit-I Unit-VI Hetero Labs Limited Unit-I Hetero Labs Limited Unit-III Sanathnagar, Hyderabad, Balanagar, Hyderabad, Nakkapally Visakhapatnam, Nakkapally Visakhapatnam, Hyderabad, (SEZ) (SEZ) Nakkapally, Visakhapatnam, Gaddapotharam, Hyderabad, Nakkapally, Visakhapatnam, Corporate Office Development of processes for APIs and technical support Ingredients Ingredients Ingredients, Intermediates Ingredients, Intermediates Ingredients Manufacturing Intermediates of It is to be noted that (Unit-IX) has 5 Production blocks and 1 Pharma section whereas Hetero Labs Limited (Unit-IX) has 6 Production blocks and 2 Pharma sections. 2 of 7 WHO Public Inspection Report (WHOPIR)
3 History of WHO and/or regulatory agency inspections Name of the Authority Inspection dates Combined inspections for HDL-IX and HLL-IX WHO Geneva inspection US FDA Inspection Portugal Authority (INFARMED) Inspection 20 th to 23 rd June th to 15 th December th to 15 th March 2013 Name of the Authority HDL-IX other Inspections Inspection dates COFEPRIS Mexican inspection WHO GMP CDSCO Local DCA renewal Inspection Dutch Healthcare Inspectorate (IGZ), The Netherlands inspection 11 th to 20 th July th August th December, th & 12 th March 2014 Name of the Authority HLL-IX other Inspections COFEPRIS (Mexico) Inspection dates 1st to 10th July-2013 WHO GMP CDSCO 28th and 29th April, 2014 Manufacturer licence issued by the state authority, Andhra Pradesh, - HDL dated 4/7/2011 till 19/10/2015 Form 25 48/VP/AP/2010/B/G - HLL dated 20/10/2010 to 19/10/2015 Form 25 47/VP/AP/2010/B/G Focus of the inspection The inspection focused on the production and control of APIs listed under Part 1. 3 of 7 WHO Public Inspection Report (WHOPIR)
4 Inspected Areas The inspection covered most of the sections of WHO GMP for Ingredients (ICH Q7), including Quality Management; Personnel; Buildings and Facilities; Process Equipment; Documentation and Records; Materials Management; Production and In-Process Controls; Packaging and Identification Labelling of APIs and Intermediates; Storage and Distribution; Laboratory Controls; Validation; Change Control; Rejection and Reuse of Materials and Complaints and Recalls. 2.1 QUALITY MANAGEMENT A system for quality assurance was established and covered most of the basic elements of GMP. An organization chart was reviewed. The quality unit was independent of production which fulfils both QA and QC responsibilities. 2.2 PERSONNEL In general, the personnel met and interviewed during the inspection were confident in what they were doing. Job descriptions of key persons were available. 2.3 BUILDINGS AND FACILITIES Overall, buildings were constructed of materials compatible with the activity being conducted. Finishes in Pharma areas were of appropriate design with surfaces easy to clean and with coved joints between walls and floors. 2.4 PROCESS EQUIPMENT The process equipment was designed, and installed satisfactorily. Also, materials used were satisfactory. In general, reactors were equipped with overheads and utilities to allow the normal range of organic reactions to be conducted. Production equipment was cleaned on a scheduled basis as per written SOPs. Cleaning status was shown by a cleaning label. Equipment calibration schedule and planned preventive maintenance (PM) program of equipment and systems was in place. Computerized systems Data capture of QC chromatography data was done electronically. 2.5 DOCUMENTATION AND RECORDS In general, the documentation system was established and maintained. Documents were approved, signed and dated by appropriate responsible persons, regularly reviewed and kept up to date. Specifications and testing procedures were available. Documents related to the batch release were stored one year after the expiry date of the batch. Most of the key quality management system procedures were issued by CQA for both HLL and HDL. In addition, manufacturing sites has site specific procedures for various production and laboratory operations. 4 of 7 WHO Public Inspection Report (WHOPIR)
5 2.6 MATERIALS MANAGEMENT In general, material management was found acceptable. Materials were received according to SOP Receipt, Verification Quarantine and sampling of Raw Materials. Sampling and dispensing booths were installed in the Raw Materials Warehouses. The reception of RM, SM and solvents is conducted according to the requirements of the SOP. SOP on vendor qualification 01/ dated 1/8/2013 provided procedure on qualification of vendors. It has been noted that vendors of API starting materials are qualified based on questionnaire, sample analysis and on-site audit. 2.7 PRODUCTION AND IN-PROCESS CONTROLS At the time of inspection, there was hardly any production running in HDL. Ritonavir Form I Stage I was started for inspection purposes. The synthesis, crystallizer and pharma area was found to be well maintained. At the time of inspection there was no production activity running in Block B and Block D. 2.8 PACKAGING AND IDENTIFICATION LABELLING OF APIs AND INTERMEDIATES There was a written procedure available describing the receipt, identification, quarantine, sampling, examination, testing and release & handling of packaging and labelling materials. While reviewing the batch manufacturing records, it had been noted that there was some ambiguity on the reconciliation of labels issued, used and returned. The existing practice does not allow retaining a printed label as a representative in the batch manufacturing record. 2.9 STORAGE AND DISTRIBUTION Facilities were available for the storage of materials and operated at acceptable level. SOP on approved vendors and storage, handling and retesting of raw materials with storage conditions LABORATORY CONTROLS There was adequate facilities, personnel, approved procedures for testing. Both HDL and HLL laboratories were equipped with modern equipment and instruments. Also, laboratories were found to be spacious and well maintained VALIDATION The Validation Master Plan was available and covered all areas. Revalidation schedule was subject to change controls listed. Process was done and critical process parameters were established. Cleaning validation was in line with daily dose and 10 ppm acceptance criteria. 5 of 7 WHO Public Inspection Report (WHOPIR)
6 2.12 CHANGE CONTROL SOP Change control provided procedure for initiation, handling of changes taken place in plant. The changes are classified into permanent and temporary changes and further divided into minor and major. A flow chart was provided on change process which included impact assessment before implementing any change followed by effectiveness of implemented changes. Product wise change register is maintained which included changes from QC, production, engineering etc REJECTION AND RE-USE OF MATERIALS There is an arrangement for reprocessing and/or reworking of a batch. Upon conducting a thorough investigation, cause for failure and corrective action proposed to reprocess the quality failure, product is determined by conducting the experiments at R&D scale. Batch production records are prepared as per the steps followed at R&D scale, and same shall be approved by QA. It is noted that reprocessed batches will be kept for stability study, and batch release will be done after meeting specification. As per company s policy, there is no reworking done on any failed product COMPLAINTS AND RECALLS Handling of customer complaints provided procedure for handling of complaints for APIs. The complaints are received through marketing and any other source and logged in complaint register. The complaints are acknowledged within 48 hours. The complaints are categorised as critical, major or minor upon receipt. Critical complaints are investigated within 24hours. Send preliminary response within 15days and final response within 30 days to complainants. There was a typo error noted on flow chart (48 hours against 24 hours for investigation of critical complaints). Trending of complaints for the year 2014 (Jan-Jun) was performed. SOP on Product recall provided instruction for recall of API either voluntarily or driven through inspection of regulatory authority. In addition, if any batch put up on stability batches shows deterioration or some quality problem, specific batch of an API can be recalled. The final responsibility to recall API is rest with CQA. Mock recall is performed every two years which is driven through a protocol. Also, a flow chart on recall procedure is available. It is learnt that mock recall is performed for both domestic and markets CONTRACT MANUFACTURERS (INCLUDING LABORATORIES) Not inspected 6 of 7 WHO Public Inspection Report (WHOPIR)
7 Part 3 Conclusion Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, as well as the corrective actions taken and planned, APIs manufactured at and Hetero labs Ltd, Unit-9 were considered to be manufactured in compliance with WHO GMP for Ingredients. All the non-compliances observed during the inspection that were listed in the full report as well as those reflected in the WHOPIR, were addressed by the manufacturer, to a satisfactory level, prior to the publication of the WHOPIR This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive. 7 of 7 WHO Public Inspection Report (WHOPIR)
Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General information
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General information Name of Manufacturer M/s. Hetero Labs Limited Unit number Production
More informationWHO Prequalification Programme: Priority Essential Medicines WHO API GMP Inspections
WHO Prequalification Programme: Priority Essential Medicines WHO API GMP Inspections Presented by Mr. Ian Thrussell Head of Inspections WHO thrusselli@who.int In this presentation: WHO-PQ: Inspection activities
More information18.H Questionnaire for preparing GMP-inspections
Questionnaire for preparing -inspections Questionnaire for preparing -inspections Here you will find answers to the following questions: What questions are typically asked during inspections based on current
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationRegulatory. Supplier Qualification A Review
Supplier Qualification A Review Abstract: It is a GMP requirement to certify the vendor to deliver high quality and safe medicines, and to prevent recalls, deaths, adverse events, and serious illness due
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationPROCESS VALIDATION: AN ESSENTIAL PROCESS IN PHARMACEUTICAL INDUSTRY
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Vijayasree et al. SJIF Impact Factor 6.647 Volume 6, Issue 3, 367-874 Review Article ISSN 2278 4357 PROCESS VALIDATION: AN ESSENTIAL PROCESS IN PHARMACEUTICAL
More informationQUALITY MANUAL DISTRIBUTION. Your Logo Here. Page 1 1 of 57. Rev.: A
Page 1 1 of 57 President Design Engineering Production Production Engineering Materials Control Purchasing Service Marketing Sales Contracts Human Resources Quality Assurance Quality Control Production
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part VIII of VIII Current article Part VIII Support QMS Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationINFORMATION REQUIRED FROM PHARMACEUTICAL FIRMS FOR REGISRATION
INFORMATION REQUIRED FROM PHARMACEUTICAL FIRMS FOR REGISRATION Part A: Details of the market Authorization holder (local agent)- 1. Name of Company: 2. Address and contact details of the company : 3. a)
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory Part
More informationQuestionnaire Layout:
Raw Material Supplier Questionnaire Introduction: This questionnaire has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations in developing
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationPrequalification of APIs
Antony Fake PhD WHO Medicines Prequalification Programme 1 2 Abbreviations API Active Pharmaceutical Ingredient FPP Finished Pharmaceutical Product API PQ API Prequalification APIMF Active Pharmaceutical
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationINDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW
International Journal of Pharmacy Review & Research www.ijprr.com INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW Vishal Sharma* and Nimrata Seth 1 Department of Pharmaceutics, Rayat Institute
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationQuality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines
Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Longe Sunday Anthony Head- Quality Assurance May & Baker Nigeria Plc. Pharmacentre, Ota, Nigeria eaglesconsult@gmail.com; Slonge@may-
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer / Iksan Plant Unit number Production Block Physical address Contact person and email
More informationAnnex 14 WHO guidelines for drafting a site master file 136
World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix
More informationRegional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators
Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationSupplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan
Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification
More informationGood Manufacturing Practices (GMPs) for Infant Formula
Good Manufacturing Practices (GMPs) for Infant Formula Nutrition Evaluation Division Bureau of Nutritional Sciences Health Products and Food Branch Health Canada 2006 Good Manufacturing Practices (GMPs)
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationGlobal Compliance Trends and Warning Letters
Contact: Charles Lu Director, Quality Carlsbad Tech Phone: (760) 431-8284 Fax: (203) 555-0101 5928 Farnsworth Ct Carlsbad, CA, 92008 www.carlsbadtech.com Global Compliance Trends and Warning Letters Governance
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationManual 058 Out of Specification Results Investigation
1 Purpose The purpose of this Guideline is to provide guidance for the investigation and response to Out of Specification (OOS) laboratory test results. 2 Scope and Applicability This Guideline applies
More informationAnnex 4. Assessment tool based on the model quality assurance system for procurement agencies: aide memoire for inspection
Annex 4 Assessment tool based on the model quality assurance system for procurement agencies: aide memoire for inspection 1. Introduction 294 2. Purpose 294 3. Scope 294 4. Assessment tool 295 293 WHO
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More informationInvestigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd
Investigating OOS for Finished Product on the Stability Program Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd Overview 1. Requirements of the commercial stability program 2. Out of Specification
More informationRisk-based Approach to Part 11 and GxP Compliance
Welcome to our E-Seminar: Risk-based Approach to Part 11 and GxP Compliance 1 Intro Common Discussion Q: Do I really need to do this? Possible Answers A: Of course! (QA) B: Who cares, I have work to do!
More informationRegulatory Expectations, Standards & Guidelines
Regulatory Expectations, Standards & Guidelines Regulatory Requirements Pharmacopeias Good Automated Manufacturing Practice (GAMP) 21 CFR Part 11 and Annex 11 Consequences of Non-Compliance 22 Regulatory
More informationIntroduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES
Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES William Garvey and Associates LLC 2016 Introduction About your instructor William (Bill) Garvey Important regulations and events Good Manufacturing
More informationOOS: Back to Basics. Compliant, Effective, Efficient PATH
OOS: Back to Basics Even with the number of trainings, seminars, online webinars and consultant guided investigations, companies are still seeing FDA 483 observations around how they are handling and investigating
More informationRisk classification guide for drug good manufacturing practices observations GUI-0023
Risk classification guide for drug good manufacturing practices observations GUI-0023 January 18, 2017 Risk classification guide for drug good manufacturing practices observations (GUI-0023) Author: Health
More informationWhite paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU
White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between
More informationQuality Manual ISO 9001:2000
Quality Manual ISO 9001:2000 Page 2 of 23 TABLE OF CONTENTS COVER PAGE...1 TABLE OF CONTENTS...2 SIGNATURES...3 QUALITY POLICY...4 INTRODUCTION...5 CORPORATE PROFILE...9 4.O QUALITY MANAGEMENT SYSTEM...10
More informationGUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART 1
GUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART 1 National Drug Authority Plot 46-48, Lumumba Avenue, P. O. Box 23096, Kampala, Uganda. Tel: +256-0414 - 255665/347391/2 Fax: +256-0414
More informationAvailable online at ScienceDirect. Procedia Engineering 132 (2015 )
Available online at www.sciencedirect.com ScienceDirect Procedia Engineering 132 (2015 ) 811 815 The Manufacturing Engineering Society International Conference, MESIC 2015 Metrological Regulations for
More informationAnnex 6. Good trade and distribution practices for pharmaceutical starting materials
Annex 6 Good trade and distribution practices for pharmaceutical starting materials Introduction 212 1. Quality management 213 2. Organization and personnel 214 3. Premises 215 4. Procurement, warehousing
More informationGMPs: Distribution Centers
SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener
More informationSession 10: The UNFPA Prequalification Site Inspection
Session 10: The UNFPA Prequalification Site Inspection Group Brainstorm: Site Inspection In your experience, in what areas have you disagreed with the inspectors? Objectives Provide overview of what inspectors
More informationGUIDELINES ON RECALL AND RAPID ALERT SYSTEM FOR DRUGS (Including Biologicals & Vaccines)
GUIDELINES ON RECALL AND RAPID ALERT SYSTEM FOR DRUGS (Including Biologicals & Vaccines) VERSION : 2017 Document No : CDSCO/RRAS Ver. : 00 Effective Date : 23/11/2012 Central Drugs Standard Control Organisation
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationOn-Site GMP Training GMP COMPLIANCE TECHNICAL
PharmaNet On-Site GMP Training GMP COMPLIANCE TECHNICAL 284 E Lake Mead Pkwy Suite C-278 Henderson, NV 89015 Phone: 702-558-0094 Fax: 702-558-0079 www.gmpseminars.com Key to Level of Program Level A: Program
More informationUNICEF Quality Assurance in the procurement of medicines
UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen 30 October 2006 Quality Assurance Centre SUPPLY DIVISION Today s presentation addresses 3 questions: How is UNICEF involved in
More informationQuality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationPromoting Quality OINDP Components- A Supplier Perspective
Promoting Quality OINDP Components- A Supplier Perspective Tom Gaspar Vice President Quality Assurance, Manufacturing and Development Support West Pharmaceutical Services IPAC-RS Conference November 2006
More informationEPICOR, INCORPORATED QUALITY ASSURANCE MANUAL
EPICOR, INCORPORATED QUALITY ASSURANCE MANUAL Revision: 6 Date 05/18/09 EPICOR, INCORPORATED 1414 E. Linden Avenue P.O. Box 1608 Linden, NJ. 07036-0006 Tel. 1-908-925-0800 Fax 1-908-925-7795 Table of Contents:
More informationQMS CO-ORDINATOR & GENERAL PROCEDURES:-
1. QMS CO-ORDINATOR & GENERAL PROCEDURES:- (1) How do you measure effectiveness of system for working of your company? How do you collect necessary information for the same? Are you getting information
More informationPIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
More informationAn is all it takes to change the way you work..!
An is all it takes to change the way you work..! IT S TIME FOR QUALITY www.quickgmp.com PAST Production was the only concern In the past the onus on production and marketing preceded every other concern.
More informationCSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017
CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection
More informationSeamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson
Seamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson Senior Management Consultant Agenda Introduction A state-of
More informationGMP MANUAL Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel
GMP MANUAL GMP MANUAL 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C (1) 1.C.2 Documentation
More informationGUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 009-11 (Part I) 1 March 2014 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I PIC/S March 2014 Reproduction
More informationBy Dr. Michael Hiob, Max Lazar, Dr. Christian Gausepohl and Dr. Christine Oechslein. Preparing for the EU GMP Inspection
By Dr. Michael Hiob, Max Lazar, Dr. Christian Gausepohl and Dr. Christine Oechslein Preparing for the EU GMP Inspection ISBN: 978-3-943267-79-2 A Process Approach to Pharmaceutical Quality Systems A Guide
More informationZOLL Document Number: 90E0021 Page 6 of 50 QUALITY SYSTEM MANUAL ZOLL Document Number: 90E0021 Page 7 of 50 1 EXECUTIVE MANAGEMENT APPROVAL... 10 2 INTRODUCTION... 11 3 QUALITY SYSTEM... 12 3.1 QUALITY
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationChallenges in Implementing Knowledge Management within ICH Q10
Challenges in Implementing Knowledge Management within ICH Q10 SYMPOSIUM - New Frontiers in Manufacturing Technology, Regulatory - Brasilia Joseph C. Famulare Vice President, Global Head Compliance and
More informationSupplier Assurance Program. CBE Pty Ltd
Supplier Assurance Program CBE Pty Ltd This training program is copyright to CBE Pty Ltd and may not be modified, reproduced, sold, loaned, hired or traded in any form without its express written permission.
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationHosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)
Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil) Kathrin Abelein Vice President Quality, R-Pharm, JSC First Russian GMP Conference 20. 22. September 2016 Agenda General information
More informationAudits must be conducted with due concern for employee safety and environmental protection.
Standard Operating Procedure Title: GMP Audit Procedure Related Documents TEM-080 Internal Audit Report Template TEM-120 Vendor Audit Report Template Form-385 Vendor Audit Questionnaire Form-445 EHS Workplace
More informationWHO GOOD PRACTICES FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES
May 2009 RESTRICTED WHO GOOD PRACTICES FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES Please address comments on this proposal, by 15 June 2009, to Dr S. Kopp, Medicines Quality Assurance Programme, World
More informationGOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL STARTING MATERIALS. REVISION
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 GOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL STARTING MATERIALS.
More informationStandard operating procedures revisited: a 2014 perspective
Pharmaceutical Pharm. Bioprocess. (2014) 2(1), 41 47 Standard operating procedures revisited: a 2014 perspective Approximately 50 years after the good manufacturing practice (GMP) regulations were first
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationBusiness Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs
Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where
More informationHow Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S)
How Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S) ASQ Northeast Pharmaceutical GMP/Quality Conference January
More informationGood Manufacturing Practice for Investigational Medicinal Products
CHAPTER 29 Good Manufacturing Practice for Investigational Medicinal Products V. EDY 1 AND M. GAMLEN 2 1 Newland GxP Consultancy, Witney, Oxon, UK 2 Pharmaceutical Development Services Ltd, UK 29.1 INTRODUCTION
More informationReference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards.
Reference Standard Characterization Steve Lane General Manager, NSF Reference Standards www.nsf-rs.org Regulatory Bodies will require that an Excipient: Be safe in the amount or dose used Meet applicable
More informationWHO guidelines on quality risk management
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationGuidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.
Guidance for Industry Process Validation: General Principles and Practices D M k T k Dr. Mark Tucker, F. Hoffman-La Roche, Ltd. Disclosures I am currently a Senior Technical Advisor at F. Hoffman -La Roche.
More informationVendor Qualification Survey
1200 West 96 th St Minneapolis, MN 55431 Ph: 952-888-7900 Fax: 952-888-2719 Vendor Qualification Survey Vendor Information Company Name: Date: Address: City: Phone Number: email address: Product or Service
More informationAUSTRALIAN CERTIFIED NON-GMO STANDARD. Version 1.0, 2016, Australian Organic Limited
AUSTRALIAN CERTIFIED NON-GMO STANDARD Version 1.0, 2016, Australian Organic Limited TABLE OF CONTENTS 1. Introduction 03 2. Purpose 04 3. Methodology 04 4. Scope 04 5. Quality Management System 04 6. Risk
More informationGMP Inspection Process. Types of GMP Inspection. Module 18 Slide 1 of 14 WHO - EDM
GMP Inspection Process Types of GMP Inspection Module 18 Slide 1 of 14 WHO - EDM Objectives 1. To review the different types of inspection 2. To examine when each is appropriate 3. To discuss inspections
More informationPCI Pharmaceutical Consulting
PCI Pharmaceutical Consulting The Role of the QP: before & after Annex 16 Presented by: Karen Ginsbury For IFF, Denmark March 2016 Responsibility Authority Responsibility Authority Having the duty to perform
More informationGMP Requirements Based On WHO Guidelines for Ayush Premium Mark
SECTION III VOLUNTARY CERTIFICATION SCHEME FOR AYUSH PRODUCTS Certification Criteria Annex A GMP Requirements Based On WHO Guidelines for Ayush Premium Mark 1. Introduction The increasing use of herbal
More informationQuality Assurance Policy and Procedures
650 Montana Ave, Suite A Las Cruces, NM 88001 (575) 522-0430 www.rmgovernmentservices.com Quality Assurance Policy and Procedures PURPOSE. The purpose of this policy is to outline the quality assurance
More informationThe long anticipated draft of the FDA s
This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based
More informationQP s experience with QRM. Fergus O Connell QA Manager AMS Laboratories
QP s experience with QRM Fergus O Connell QA Manager AMS Laboratories December 2011 Risk Management in a QPs role Validation Master Plan Risk Review Early issues Human Error Risk Influencing Factors EU
More information